Why IMU is a multi multi bagger, page-23529

Hawkbar,

Yes we are discussing the MAST trial 20 stable disease out of 40 evaluable patients is outstanding. Take out the early low dose patients. Take out the nearly dead. And the numbers are outstanding.

YF spoke honestly about it working in humans as it did in animals. He was not able to trial low doses in extremely compromised humans who had very advanced cancer and been irradiated and poison with chemo for months or maybe years.

Now we know treat them early with CF33 before chemo and radiation. Then the numbers will rise significantly. BIG PHARMA will come to the same conclusion as LC “outstanding “.

As LC said you “ don’t normally see this in any phase 1 trials.”

So far everything is going very well. One last checkpoint for us ONCARLYTICS working as it should in humans. I doubt the ONCARLYTICS presentation at ASCO in a few weeks will be bad news. The only question is how much data will we see.

If not this time it won’t be long. LC will be busting her britches to show the world what ONCARLYTICS can do.

On a different matter, maybe PD1Vax might our first deal. LC was recently talking about monetising some of our assets. And there it is in yesterday’s video. How PD1 inhibitors have hit the headlines. And we just happen to have one that’s surplus to requirements.